Akero Therapeutics, Inc. (Nasdaq - AKRO)

Akero Therapeutics, Inc. (Nasdaq – AKRO)

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Akero Therapeutics, Inc. (Nasdaq – AKRO)

BALA CYNWYD – October 9, 2025/Globe Newswire/ – Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Akero Therapeutics, Inc. (“Akero” or the “Company) (Nasdaq – AKRO) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Novo Nordisk A/S (“Novo Nordisk”) for $54.00 per share in cash at closing and a non-transferable Contingent Value Right (“CVR”). Each CVR will entitle its holder to receive a cash payment of $6.00 per share upon full U.S. regulatory approval of efruxifermin (“EFX”) for treatment of compensated cirrhosis due to MASH by June 30, 2031.

The investigation concerns whether the Akero Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company’s shareholders.

If you own shares of Akero stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman by email at clients@brodsky-smith.com, or call toll free 855-576-4847.

Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.

Fill out this Single Case form

* Mr/Mrs/Ms (Select One)

* First Name:

* Last Name:

* Address:

* City:

* State:

* Zip Code:

* Country:

* Email Address:

* Phone Number:

*Number of Shares Owned:

*Date purchased:

* Are you currently an employee of the Company?:

By clicking on the submit button, I acknowledge that I have downloaded and read both the Merger Retainer Agreement and
Class Representative Rights and Responsibilities documents, and agree to retain Brodsky & Smith, LLC to represent them in the 1st United Bancorp, Inc shareholder matter. Brodsky & Smith, LLC will prosecute the action on a contingent fee basis and will advance all costs and expenses.